Neutropenia - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neutropenia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Neutropenia - Pipeline Review, H1 2015', provides an overview of the Neutropenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neutropenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neutropenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Neutropenia Overview 9
Therapeutics Development 10
Pipeline Products for Neutropenia - Overview 10
Pipeline Products for Neutropenia - Comparative Analysis 11
Neutropenia - Therapeutics under Development by Companies 12
Neutropenia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Neutropenia - Products under Development by Companies 19
Neutropenia - Companies Involved in Therapeutics Development 21
Apotex, Inc. 21
Biocon Limited 22
Biosidus S.A. 23
Cellerant Therapeutics, Inc. 24
Chong Kun Dang Pharmaceutical Corp. 25
Coherus BioSciences, Inc. 26
CSL Limited 27
Gamida Cell Ltd. 28
Genexine, Inc. 29
Inbiopro Solutions Pvt. Ltd. 30
Ligand Pharmaceuticals, Inc. 31
NAL Pharmaceuticals Ltd. 32
Pfenex Inc. 33
Richter Gedeon Nyrt. 34
Sandoz International GmbH 35
Taiho Pharmaceutical Co., Ltd. 36
Teva Pharmaceutical Industries Limited 37
Therapeutic Proteins International, LLC 38
Toko Pharmaceutical Industries Co., Ltd. 39
USV Limited 40
Neutropenia - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
(piperacillin sodium + tazobactam sodium) - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ACN-8337 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CSL-324 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
filgrastim - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
filgrastim - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
filgrastim - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
filgrastim (recombinant) - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
GC-003 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
granulocyte colony-stimulating factor biobetter - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GXG-3 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IBPB-004IG - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LG-7455 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
lipegfilgrastim - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
pegfilgrastim - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pegfilgrastim - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
pegfilgrastim - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
pegfilgrastim - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
pegfilgrastim - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
pegfilgrastim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
pegfilgrastim - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
pegfilgrastim - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
pegfilgrastim - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
pegfilgrastim - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pegfilgrastim - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
romyelocel-L - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ST-7 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tamibarotene - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Neutropenia - Recent Pipeline Updates 79
Neutropenia - Dormant Projects 83
Neutropenia - Product Development Milestones 85
Featured News & Press Releases 85
Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 85
Feb 17, 2015: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil) 85
Dec 17, 2014: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 85
Jul 02, 2014: Application for the Additional Indication of Febrile Neutropenia for ZOSYN, an Injectable Antibiotic Combined with ß-Lactamase Inhibitor 86
Dec 09, 2013: Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at the 55th Annual Meeting of the American Society of Hematology 86
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics 87
Dec 12, 2011: Ligand Announces Positive Preclinical Data On Small-Molecule GCSF Receptor Agonist At ASH Annual Meeting 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables

Number of Products under Development for Neutropenia, H1 2015 10
Number of Products under Development for Neutropenia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Neutropenia - Pipeline by Apotex, Inc., H1 2015 21
Neutropenia - Pipeline by Biocon Limited, H1 2015 22
Neutropenia - Pipeline by Biosidus S.A., H1 2015 23
Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H1 2015 24
Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 25
Neutropenia - Pipeline by Coherus BioSciences, Inc., H1 2015 26
Neutropenia - Pipeline by CSL Limited, H1 2015 27
Neutropenia - Pipeline by Gamida Cell Ltd., H1 2015 28
Neutropenia - Pipeline by Genexine, Inc., H1 2015 29
Neutropenia - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 30
Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 31
Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 32
Neutropenia - Pipeline by Pfenex Inc., H1 2015 33
Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2015 34
Neutropenia - Pipeline by Sandoz International GmbH, H1 2015 35
Neutropenia - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 36
Neutropenia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 37
Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H1 2015 38
Neutropenia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2015 39
Neutropenia - Pipeline by USV Limited, H1 2015 40
Assessment by Monotherapy Products, H1 2015 41
Assessment by Combination Products, H1 2015 42
Number of Products by Stage and Target, H1 2015 44
Number of Products by Stage and Mechanism of Action, H1 2015 46
Number of Products by Stage and Route of Administration, H1 2015 48
Number of Products by Stage and Molecule Type, H1 2015 50
Neutropenia Therapeutics - Recent Pipeline Updates, H1 2015 79
Neutropenia - Dormant Projects, H1 2015 83
Neutropenia - Dormant Projects (Contd..1), H1 2015 84